{"version":"1.0","type":"link","title":"Coopting Germline BRCA2 Mutation With an Available PARP Inhibitor to Manage Resistance to EGFR Targeted Therapy in EGFR-Mutated Lung Cancer: Combination of Olaparib With Osimertinib.","author_name":"Kwon H 외","author_url":"https://prs-insight.online/author/Kwon%20H","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/94689","thumbnail_width":1200,"thumbnail_height":630}